Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 9;63(12):e01510-19.
doi: 10.1128/AAC.01510-19. Epub 2019 Sep 30.

Activity of a novel 1,3-beta-D-glucan Synthase Inhibitor, Ibrexafungerp (formerly SCY-078), Against Candida glabrata

M Ghannoum  1 , L Long  2 , N Isham  2 , C Hager  2 , R Wilson  2 , K Borroto-Esoda  3 , S Barat  3 , D Angulo  3
Affiliations

Activity of a novel 1,3-beta-D-glucan Synthase Inhibitor, Ibrexafungerp (formerly SCY-078), Against Candida glabrata

M Ghannoum et al. Antimicrob Agents Chemother. .

Abstract

Ibrexafungerp (formerly SCY-078), a novel glucan synthase inhibitor with oral availability, was evaluated for activity against Candida glabrata Susceptibility of clinical strains to Ibrexafungerp was determined by microdilution and time kill assays. The MIC range against wild type strains was 1-2 μg/mL. IBX was also active against the majority of echinocandin-resistant strains. Time kill studies showed a 4 to 6-log reduction in growth at concentrations of 0.25 to 4 μg/ml at 24 and 48 hr.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Time-kill curves for ibrexafungerp (formerly SCY-078) and micafungin (MICA) against caspofungin-susceptible and caspofungin-resistant C. glabrata strains (strains 9547 and 64-74, respectively).
See this image and copyright information in PMC

References

    1. Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M. 2013. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). J Antimicrob Chemother 68:858–863. doi:10.1093/jac/dks466. - DOI - PubMed
    1. Jiménez-Ortigosa C, Paderu P, Motyl MR, Perlin DS. 2014. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates. Antimicrob Agents Chemother 58:1248–1251. doi:10.1128/AAC.02145-13. - DOI - PMC - PubMed
    1. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. 2010. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 48:2373–2380. doi:10.1128/JCM.02390-09. - DOI - PMC - PubMed
    1. Garcia-Effron G, Chua DJ, Tomada JR, DiPersio J, Perlin DS, Ghannoum M, Bonilla H. 2010. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob Agents Chemother 54:2225–2257. doi:10.1128/AAC.00998-09. - DOI - PMC - PubMed
    1. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. CLSI document M27-S4 Clinical and Laboratory Standards Institute, Wayne, PA.

LinkOut - more resources